First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
NCT04840784
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
9
Enrollment
INDUSTRY
Sponsor class
Stopped
The reasons for early termination is due to slow recruitment
Conditions
NHL
Leukemia
Interventions
DRUG:
ETH-155008
Sponsor
Shengke Pharmaceuticals Pty Ltd